Inventor · disambiguated record
Liusong Yin
Also filed as: YIN LIUSONG
6 granted patents·24 pending applications·3 citations·filing 2018–2023
67Inventor score
Files withNANJING GENSCRIPT BIOTECH CO LTD17SHENGHE CHINA BIOPHARMACEUTICAL CO LTD11NANJING LEGEND BIOTECH CO LTD1SHENGHE CHINA BIOPHARMACEUTICAL CO1
Top patents by PatentIndex Score
30 records- 0179US12258418B2Claudin18.2 binding moieties and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2019·Granted Mar 25, 2025·2 cites·20 claims
- 0274US12168688B2Antibodies and variants thereof against PD-L1NANJING LEGEND BIOTECH CO LTD·Filed 2018·Granted Dec 17, 2024·1 cites·21 claims
- 0356US2024352128A1ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16aNANJING GENSCRIPT BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 0450US2024218065A1Multispecific antigen-binding protein and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO·Filed 2022·Application pending·0 cites
- 0550US2025243287A1Anti-ccr8 antibody or antigen-binding fragment thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0649US2025092140A1Bispecific antibody binding to b7h3 and nkp30, and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0748US2024392007A1Heterodimeric protein and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0848US2023064703A1Anti-gitr antibodies and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 0947US2024327543A1Multispecific antigen-binding protein and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1047US2024336682A1Multispecific antigen-binding protein and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1147US2023093512A1Fusion proteins and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1247US2023125301A1Multispecific anti-claudin-18.2 constructs and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1346US12358987B2Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Granted Jul 15, 2025·0 cites·18 claims
- 1446US2024034784A1Antibodies targeting human claudin 18.2 and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1546US2022235133A1Monoclonal antibody-cytokine fusion protein dimer and application thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1646US2025250335A1Antibody against ceacam5 and ceacam6, and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1745US2022267475A1Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1845US2025320309A1Bispecific antigen binding proteinSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1945US2022267436A1Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2045US2022289848A1Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2143US12269890B2Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2019·Granted Apr 8, 2025·0 cites·15 claims
- 2243US2022220204A1Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2343US2022332848A1Anti-cd47/anti-ctla-4 bispecific antibody and preparation method therefor and application thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2442US12098204B2Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2019·Granted Sep 24, 2024·0 cites·15 claims
- 2541US2024150460A1Anti-nkp30 antibody and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2641US2025263499A1Anti-cd24 antibody and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2741US2022396615A1Anti-human il6 monoclonal antibodies, preparation method therefor and use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2018·Application pending·0 cites
- 2840US12037396B2Humanized anti-human CTLA4 monoclonal antibody, preparation method therefor and use thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2019·Granted Jul 16, 2024·0 cites·19 claims
- 2940US2025043015A1Anti-tnfr2 single domain antibody, and preparation method therefor and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3040US2025320303A1Anti-tnfr2 antibody and preparation method and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Liusong Yin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →